A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Launched by CLOUDBREAK THERAPEUTICS, LLC · Jul 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new eye drop treatment called CBT-001 for people with pterygium, a condition where a growth forms on the surface of the eye, often leading to redness and discomfort. The trial aims to see if using low and high doses of these eye drops twice a day for two years can help reduce eye redness and stop the growth from getting worse.

To participate in this trial, you need to have pterygium with visible redness in the eye and be at least 43 years old. However, if you have had surgery to remove pterygium in the last six months, you won't be eligible. If you join the study, you’ll receive either the CBT-001 eye drops or a placebo (a substance that looks like the medication but has no active ingredients) to compare the effects. This trial is currently recruiting participants of all genders, and it’s an important step in finding effective treatments for this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pterygium with conjunctival hyperemia
• Exclusion Criteria:
• • Pterygium removal within the last 6 months